Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00085450" target="_blank" >RIV/00216224:14110/15:00085450 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/15:00063842
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1509388" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1509388</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1509388" target="_blank" >10.1056/NEJMoa1509388</a>
Alternative languages
Result language
angličtina
Original language name
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Original language description
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trialto compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma. METHODS We randomly assigned 269 previously untreated patients who were 65 years of age or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlorambucil. The primary end point was progression-free survival as assessed by an independent review committee. RESULTS The median age of the patients was 73 years. During a median follow-up period of 18.4 months, ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 months), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil (haz
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
373
Issue of the periodical within the volume
25
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
2425-2437
UT code for WoS article
000366461400009
EID of the result in the Scopus database
—